<DOC>
	<DOCNO>NCT02090153</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety S-1 plus Leucovorin ( 1 week 1 week ) first-line treatment patient metastatic recurrent gastric cancer .</brief_summary>
	<brief_title>Study S-1 Plus LV Advanced Gastric Cancer</brief_title>
	<detailed_description>Patients enrol study orally treat S-1 dos 40 mg ( body surface area ( BSA ) &lt; 1.25 m2 ) , 50 mg ( 1.25≤BSA &lt; 1.50 m2 ) 60 mg ( BSA≥1.50 m2 ) b.i.d . day 1-7 combination LV give simultaneously ﬁxed dose 25 mg b.i.d . day 1-7 , follow 7 day rest . Treatment course repeat every 2 week . Treatment continue progressive disease ( PD ) , unacceptable toxicity patient refusal .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>histologically conﬁrmed metastatic recurrent gastric cancer least one measurable lesion RECIST criterion age ≥ 18 adequate oral intake previous radiotherapy , immunotherapy , biotherapy , hormonotherapy chemotherapy within 5 year ( adjuvant chemotherapy without S1 allow ﬁnished 6 month enrollment ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 adequate bone marrow function , hepatic function renal function history hypersensitivity S1 LV , usage drug interact S1 serious concomitant condition ( severe heart disease , pulmonary ﬁbrosis , intestinal obstruction , enteroplegia , renal failure , liver failure , preexist sensory neuropathy ≥ grade 2 , uncontrolled infection , psychogenic disorder , human immunodeﬁciency virus infection , severe diarrhea , nausea , vomit , severe ascites pleural effusion , etc . ) extensive bone metastasis , brain metastasis meningeal metastasis another synchronous cancer surgery within 3 week enrollment participate clinical study woman pregnant , nursing infant , men conceive child</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Advance Gastric Cancer ,</keyword>
	<keyword>S-1 plus leucovorin ,</keyword>
	<keyword>ORR ,</keyword>
	<keyword>OS ,</keyword>
	<keyword>TTP ,</keyword>
	<keyword>TTF ,</keyword>
	<keyword>Adverse event ,</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>